Aptimmune Biologics announced that it has completed its Series B funding initiative, raising more than $6 million from several investors. This increases the combined total investment to almost $9 million, which the company generated through three rounds of funding.

“Aptimmune is thrilled to receive strong investor support during this critical time in our development,” Aptimmune chief executive officer Aaron Gilbertie said. “The Series B funds will provide the required resources to continue commercialization of Barricade, our revolutionary inactivated mucosal vaccine formulation. In addition, the fresh cash infusion will allow us to expand our vaccine platform to other antigens important to veterinarians and swine producers around the globe.”

Participants in the company’s Series B funding include St. Louis Arch Angels, Arsenal Capital Management, Missouri Technology Corp., Cultivation Capital, The Yield Lab and various Midwest-based angel investors.

“St. Louis Arch Angels invested in Aptimmune starting in the fall 2016, and since that time, we’ve observed the company’s steady progress -- technically and commercially,” said Steve Wilhelm with Arch Angels. “We believe in Aptimmune’s mission and team and are pleased to extend our investment in Aptimmune as it changes vaccine paradigms and improves outcomes for customers.”

Relocation

In addition, Aptimmune announced that it is relocating its headquarters and laboratory from Champaign, Ill., to the Bio-Research & Development Growth (BRDG) Park in St. Louis, Mo. Gilbertie said the move is due, in large part, to the exceptional financial and logistics support the company has received from investors and other businesses in the St. Louis area.

“We had outgrown our original facilities, and after thorough evaluation of several sites nationwide, we made the decision to relocate our headquarters and laboratory to BRDG Park in St. Louis,” Gilbertie explained.

The Missouri Technology Corp., which supports innovation and entrepreneurship in the state, helped bring Aptimmune to Missouri by investing in the Series B financing through the Missouri IDEA Fund Program.

“Aptimmune represents the type of fast-growing, next-generation animal health company that Missouri is excited to support,” said Bill Anderson, executive director of Missouri Technology.

Aptimmune’s new address is 1005 N. Warson Rd., St Louis, Mo. 63132.

Aptimmune Biologics specializes in developing and marketing a portfolio of inactivated mucosal vaccines that provide answers for the most costly diseases affecting the swine industry. Aptimmune’s first vaccines are focused on addressing two major viral respiratory pathogens: porcine reproductive and respiratory syndrome virus and influenza A virus in swine.